Susquehanna International Group
ATNM icon

Susquehanna International Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Susquehanna International Group’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-39,500
Closed -$292K – 11923
2024
Q2 		$292K Sell
39,500
-14,400
-27% -$119K ﹤0.01% 9501
2024
Q1 		$422K Buy
53,900
+20,400
+61% +$131K ﹤0.01% 8919
2023
Q4 		$170K Buy
33,500
+3,000
+10% +$15.4K ﹤0.01% 10845
2023
Q3 		$181K Sell
30,500
-35,800
-54% -$238K ﹤0.01% 10340
2023
Q2 		$492K Sell
66,300
-1,200
-2% -$10.2K ﹤0.01% 8358
2023
Q1 		$638K Buy
67,500
+26,000
+63% +$274K ﹤0.01% 7972
2022
Q4 		$442K Buy
41,500
+16,000
+63% +$162K ﹤0.01% 8191
2022
Q3 		$188K Sell
25,500
-69,600
-73% -$433K ﹤0.01% 10933
2022
Q2 		$457K Buy
95,100
+41,100
+76% +$233K ﹤0.01% 8499
2022
Q1 		$276K Buy
54,000
+32,300
+149% +$170K ﹤0.01% 10471
2021
Q4 		$130K Sell
21,700
-39,300
-64% -$295K ﹤0.01% 11948
2021
Q3 		$540K Buy
61,000
+29,600
+94% +$206K ﹤0.01% 9177
2021
Q2 		$248K Buy
31,400
+5,800
+23% +$45.5K ﹤0.01% 11157
2021
Q1 		$195K Sell
25,600
-27,500
-52% -$234K ﹤0.01% 11443
2020
Q4 		$414K Buy
53,100
+39,200
+282% +$426K ﹤0.01% 8669
2020
Q3 		$135K Buy
+13,900
New +$153K ﹤0.01% 9753
2016
Q3 		– Sell
-543
Closed -$29K – 8367
2016
Q2 		$29K Sell
543
-620
-53% -$34.6K ﹤0.01% 8329
2016
Q1 		$69K Sell
1,163
-367
-24% -$23.2K ﹤0.01% 8578
2015
Q4 		$148K Buy
1,530
+90
+6% +$5.98K ﹤0.01% 8656
2015
Q3 		$76K Sell
1,440
-1,467
-50% -$98K ﹤0.01% 9252
2015
Q2 		$231K Buy
+2,907
New +$248K ﹤0.01% 9036

Other funds holding ATNM

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group's ATNM Position: Q1 2026 in Review

Susquehanna International Group increased its Actinium Pharmaceuticals (ATNM) stake by 50% in Q1 2026, buying an estimated $49.4K and bringing the position to 123,998 shares worth $123K. The position accounts for ﹤0.01% of the portfolio, ranked #12197.

Susquehanna International Group first reported a position in ATNM in Q2 2015 and has held it in 33 quarters since. The position peaked at $2.31M in Q1 2023. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

  • Susquehanna International Group held 123,998 shares of Actinium Pharmaceuticals worth $123K as of Q1 2026.
  • Susquehanna International Group bought 41,524 Actinium Pharmaceuticals shares in Q1 2026, an estimated $49.4K.
  • Actinium Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12197 holding.
  • Susquehanna International Group first reported a position in Actinium Pharmaceuticals in Q2 2015 and has held it in 33 quarters since.
  • Susquehanna International Group's Actinium Pharmaceuticals position peaked at $2.31M in Q1 2023.
  • 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.